Skip to main content
  • Loading metrics

Risk Factors Associated with Ebola and Marburg Viruses Seroprevalence in Blood Donors in the Republic of Congo

  • Nanikaly Moyen ,

    Affiliations Aix Marseille University, IRD French Institute of Research for Development, EHESP French School of Public Health, EPV UMR_D 190 "Emergence des Pathologies Virales", Marseille, France, Centre National de Transfusion Sanguine, Brazzaville, Republic of Congo, IHU Méditerranée Infection, APHM Public Hospitals of Marseille, Marseille, France

  • Laurence Thirion,

    Affiliation Aix Marseille University, IRD French Institute of Research for Development, EHESP French School of Public Health, EPV UMR_D 190 "Emergence des Pathologies Virales", Marseille, France

  • Petra Emmerich,

    Affiliation Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany

  • Amelia Dzia-Lepfoundzou,

    Affiliation Centre National de Transfusion Sanguine, Brazzaville, Republic of Congo

  • Hervé Richet,

    Affiliation IHU Méditerranée Infection, APHM Public Hospitals of Marseille, Marseille, France

  • Yannik Boehmann,

    Affiliation Aix Marseille University, IRD French Institute of Research for Development, EHESP French School of Public Health, EPV UMR_D 190 "Emergence des Pathologies Virales", Marseille, France

  • Yannick Dimi,

    Affiliation Centre National de Transfusion Sanguine, Brazzaville, Republic of Congo

  • Pierre Gallian,

    Affiliations Aix Marseille University, IRD French Institute of Research for Development, EHESP French School of Public Health, EPV UMR_D 190 "Emergence des Pathologies Virales", Marseille, France, IHU Méditerranée Infection, APHM Public Hospitals of Marseille, Marseille, France, Etablissement Français du Sang Alpes Méditerranée, Marseille, France

  • Ernest A. Gould,

    Affiliation Aix Marseille University, IRD French Institute of Research for Development, EHESP French School of Public Health, EPV UMR_D 190 "Emergence des Pathologies Virales", Marseille, France

  • Stephan Günther,

    Affiliation Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany

  • Xavier de Lamballerie

    Affiliations Aix Marseille University, IRD French Institute of Research for Development, EHESP French School of Public Health, EPV UMR_D 190 "Emergence des Pathologies Virales", Marseille, France, IHU Méditerranée Infection, APHM Public Hospitals of Marseille, Marseille, France



Ebola and Marburg viruses (family Filoviridae, genera Ebolavirus and Marburgvirus) cause haemorrhagic fevers in humans, often associated with high mortality rates. The presence of antibodies to Ebola virus (EBOV) and Marburg virus (MARV) has been reported in some African countries in individuals without a history of haemorrhagic fever. In this study, we present a MARV and EBOV seroprevalence study conducted amongst blood donors in the Republic of Congo and the analysis of risk factors for contact with EBOV.

Methodology and Findings

In 2011, we conducted a MARV and EBOV seroprevalence study amongst 809 blood donors recruited in rural (75; 9.3%) and urban (734; 90.7%) areas of the Republic of Congo. Serum titres of IgG antibodies to MARV and EBOV were assessed by indirect double-immunofluorescence microscopy. MARV seroprevalence was 0.5% (4 in 809) without any identified risk factors. Prevalence of IgG to EBOV was 2.5%, peaking at 4% in rural areas and in Pointe Noire. Independent risk factors identified by multivariate analysis were contact with bats and exposure to birds.


This MARV and EBOV serological survey performed in the Republic of Congo identifies a probable role for environmental determinants of exposure to EBOV. It highlights the requirement for extending our understanding of the ecological and epidemiological risk of bats (previously identified as a potential ecological reservoir) and birds as vectors of EBOV to humans, and characterising the protection potentially afforded by EBOV-specific antibodies as detected in blood donors.

Author Summary

Ebola and Marburg viruses cause haemorrhagic fevers often fatal to humans. Here, we looked for antibodies to Ebola and Marburg viruses (i.e., markers of previous contact with these viruses) in Congolese blood donors with no previous history of haemorrhagic fever. We found serologic evidence for contact with Marburg and Ebola viruses in 0.5% and 2.5% of blood donors, respectively. The circulation of Marburg virus occurs at a very low rate without any identified risk factor. In contrast, prevalence to Ebola virus was peaking at 4% in rural areas and in Pointe Noire city. Importantly, we identified that contacts with bats and birds constituted two independent environmental determinants of exposure. This study confirms that contact with Ebola virus is not infrequent in Congo and can occur in the absence of haemorrhagic fever. It highlights the requirement for further investigating the role of bats and birds in the ecological cycle of Ebola, and for determining whether asymptomatic contact with Ebola virus can provide subsequent protection against severe forms of the Ebola disease.


Marburg and Ebola viruses (family Filoviridae, genera Marburgvirus and Ebolavirus) cause severe Viral Haemorrhagic Fever (VHF) in humans, with a high fatality rate in symptomatic cases [1,2,3]. They appear to infect and persist in some species of fruit bats, that may serve as natural reservoirs for these viruses [4,5,6,7,8,9]. Non-human primates have been a source of human infections however they are not thought to be the reservoir as they develop severe, fatal illness when infected [10].

The genus Marburgvirus currently consists of a single species Marburg marburgvirus, of which the recognised members are Marburg virus (MARV) and Ravn virus [11,12]. The first cases of Marburg haemorrhagic fever (MHF) occurred in Germany and Serbia (in the former Yugoslavia) in 1967 and were linked to laboratory work using tissues dissected from African green monkeys imported from Uganda [13,14]. The first major outbreak of MHF occurred in Democratic Republic of the Congo (DRC, formerly Zaire), from 1998 to 2000 [15,16]. A second, even more devastating outbreak occurred in Angola in 2004–2005 with a reported case fatality rate (CFR) of almost 90% [17,18].

In Nigeria and DRC, seroprevalence studies identified antibodies to MARV in less than 2% of apparently healthy people selected in general population in Nigeria and amongst healthcare workers and general population in DRC [19,20]. In the Central African Republic (CAR), antibodies to MARV were observed in both Pygmy (0.7–5.6%) and non-Pygmy (0.0–3.9%) populations [21]. An African serosurvey of VHF (Crimean-Congo haemorrhagic fever, Rift Valley fever, Lassa, Hantaan, EBOV and MARV), conducted in the 1980s in the Central African general population, reported low prevalence values: 0.3% in N’Djamena (Tchad), 2.6% in Bioco Island (Equatorial Guinea) and, in the Republic of Congo, 3% in Pointe-Noire but no seropositive sera to MARV detected in people in Brazzaville [22]. To date, no case of MHF has been reported in the Republic of Congo.

The genus Ebolavirus includes five species: Zaire ebolavirus (Ebola virus: EBOV), Sudan ebolavirus, Taï Forest ebolavirus, Reston ebolavirus and Bundibugyo ebolavirus [11,12]. The genus Ebolavirus is primarily African in origin, with the exception of the species Reston ebolavirus which is Asian [23]. EBOV was first identified in 1976, in Southern Sudan [24] and in the North of DRC [25,26]. Since then, outbreaks have been described in several other African countries (the Republic of Congo, Ivory Coast, DRC, Gabon, Sudan, Uganda, Guinea, Sierra Leone and Liberia) [1,27,28,29,30,31,32,33,34], with reported (CFR) frequently exceeding 50% amongst symptomatic patients. In the Republic of Congo where the current study took place, several outbreaks of (Zaire) EBOV were reported in the North of the country (2001 in Olloba-Mbomo, 2002 in Kéllé, 2003 in Mbandza-Mbomo), with 75 to 89% reported fatality rates [35,36,37].

In previous seroprevalence studies, amongst 1,517 apparently healthy persons tested in five regions of the Cameroon, a positive rate of 9.7% was found with highest rates amongst Pygmies (14.5%), young adults (11.6%) and rain forest farmers (13%) [38]. In CAR, the seropositivity rate was 5.3% and Pygmies appeared to have a higher seroprevalence than non-Pygmies (7% versus 4.2%) [21]. During the 1995 outbreak of Ebola virus disease in the region of Kikwit (Democratic Republic of Congo), villagers had a greater chance of exposure (9.3%) than forest and city workers (2.2%) [39]. In a large study conducted in 220 villages in Gabon (4,349 individuals enrolled), antibodies against EBOV were detected in 15.3% of those tested, with the highest levels in forested regions (17.6% and 19.4% respectively in forest and deep forest areas), suggesting the occurrence of mild or asymptomatic infections [40,41]. In the Republic of Congo, seroprevalence values reported in the late 1980's were 7.8% in Pointe-Noire and 6.2% in Brazzaville [22].

In Sierra Leone, in 2006–2008, among 253 febrile patients negative for Lassa fever and malaria, antibodies against EBOV and MARV were detected in respectively 8.2% et 3.2% of the samples [42].

In this study, we present an analysis of MARV and EBOV seroprevalence amongst blood donors in the Republic of Congo in 2011 and we report associated risk factors for contact with EBOV.

Materials and Methods

Study Design

A MARV and EBOV seroprevalence study was performed in 2011 in the Republic of Congo, using a prospective cohort of blood donors.


Field samples for the study were collected from March to July 2011, in the Republic of Congo (Fig 1) in urban areas (Brazzaville and Pointe-Noire) and in rural locations (Gamboma, Owando, Oyo and Ewo). Ewo is the capital of the Department of Cuvette-Ouest, where all previous EBOV outbreaks occurred.

Fig 1. Map of Congolese study sites.

Rural locations and Pointe-Noire city (circles); Brazzaville, the capital (square). Brackets: number of positive samples/ total of samples.

This study was performed in collaboration with the Centre National de Transfusion Sanguine (CNTS) of Congo; the Virology Laboratory UMR_D 190 "Emergence des Pathologies Virales" (Aix-Marseille University, IRD French Institute of Research for Development, EHESP French School of Public Health), Marseille, France and the Virology Laboratory of Bernhard-Nocht-Institut für Tropenmedizin, Hamburg, Germany.

Population Studied

Blood donors of both genders were included. The criteria for enrollment were eligibility for blood donation and provision of informed consent without specific limiting factors. The age of blood donors ranged from 18 to 65 years.

Ethical Considerations

Serum samples for serological analyses were collected in collaboration with the CNTS. Informed, written consent was obtained from each person enrolled in the study and the consent procedure was approved by the Congolese Research in Health Sciences Ethics Committee (N° 00000065 DGRST/CERSSA).

Data Collection

A structured questionnaire was administered face-to-face, in the official language (French) and/or in national languages (Lingala or Kutumba). All questionnaires were completed by the medical personnel conducting the interviews.

The following data were collected: socio-demographic circumstances, domestic characteristics (age, gender, occupation, residence, size of household, type of house, water resource, usage of mosquito nets), environmental characteristics (animal contacts and/or consumption), travel outside the country during their lifetime, history of haemorrhagic fever (in family or personal).


Venous blood samples were drawn using two 4 mL plain tubes which were immediately centrifuged. Sera were kept at -80°C until use. Aliquots were inactivated at 56°C for 30 min and transferred to the Virology Laboratory of the Bernhard-Nocht-Institut (BNI) in Hamburg for serological assays.

Serological Tests

Serum IgG antibodies specific for EBOV and MARV were titrated using indirect double-immunofluorescence microscopy assays which were recorded as positive if reciprocal end point titres were ≥20 [43].

Antigens consisted of acetone-fixed Vero cells infected with Ebola virus (strain ATCC 1978) or Marburg virus (strain Popp 1967). Cultivation of the viruses was carried out in an approved and compliant BLS4 laboratory in BNI.

Serum samples were tested as serial twofold dilutions from 1:20 to ≥ 1:160 and antibodies were detected with a Fluorescein isothiocyanate (FITC) labelled anti-human IgG antibody-conjugate. Cell smears were counterstained with specific anti-Ebola or anti-Marburg nucleocapsid monoclonal antibodies (provided by the Institute of Virology, University of Marburg) using a rhodamine-anti-mouse conjugate as secondary antibody [44]. As positive controls for Ebola virus, we used (i) a human polyclonal antibody for the first IF with a titre at 2,560 (IgG) and (ii) a mouse monoclonal antibody with a titre at 1,280 (IgG). As positive controls for Marburg virus, we used (i) a human polyclonal antibody for the first IF with a titre at 1,280 (IgG) and (ii) a mouse monoclonal antibody with a titre at 640 (IgG).

This “double immunofluorescence” protocol provides a much higher specificity than regular immunofluorescence assays, since only antibodies that detect filoviral antigens in co-localisation with a monoclonal antibody are considered.

Statistical Analysis

Statistical analyses were performed using the IBM SPSS statistic 21 software. Analyses aiming at analysing risk factors for seropositivity included univariate, stratified and multivariate analyses. The Fisher’s exact test was used to compare proportions in univariate analysis and the ANOVA test to compare means. The Pearson’s test was used for stratified analysis.

All statistical analyses were performed at the 95% confidence level. The association between anti-EBOV IgG seropositivity and risk factors was determined by binary logistic regression analysis. Stratified analysis based on sex, age and area were performed. The significant variables in univariate analysis were entered in the multivariate model. The quality of the multivariate model was assessed with Hosmer-Lemeshow’s test.


Sociodemographic characteristics are presented in Table 1. Overall, 809 blood donors provided serum samples; 734 (90.7%) lived in urban areas (62.9% and 27.8% in Brazzaville and Pointe-Noire, respectively), 370 (45.7%) of which were younger than 30 years old (yo) with a median age of 31. The gender ratio (Male/Female) was 3.02. Most blood donors lived in a modern house 723 (89.4%). The two most common occupations were “student” (20.9%) and “unemployed” (26.5%).

Table 1. Socio-demographic characteristics of blood donors in study areas, March-July 2011.

Epidemiological analyses of EBOV and MARV infections were performed separately. However, the same potential risk factors for seropositivity (gender, age, household size, occupation, mosquito net, travel risk, exposure to rodents/forests animals, and consumption of forests animals) were assessed for both viruses.

Individual titres of the MARV and EBOV-positives are presented in Table 2.

Table 2. Individual titres of the EBOV and MARV-positives.

MARV-Specific IgG Seroprevalence

IgG to MARV was identified in 0.5% of the donors tested (4 in 809). Seropositivity could not be significantly associated with any of the risk factors investigated in the individual questionnaire. Antibodies to MARV were detected exclusively in male blood donors from Brazzaville who had all been in contact (touching and catching) with rodents (mice and rats), but this is a common feature in out cohort (>80% of the donors reported such contact). Three out of four were students (median age 23) and one (55yo) was an office worker. None had been in contact with (or had eaten) forest animals or bats. The titre of IgG in positive donor ranged from 80 to 160.

EBOV-Specific IgG Seroprevalence

The overall prevalence of positivity for IgG when tested against EBOV was 2.5% (20 in 809). It was 1.6% (8 in 509) in Brazzaville, 4% (3 in 75) in the rural locations (Gamboma, Owando, Oyo and Ewo) and 4% (9 in 225) in Pointe-Noire.

Univariate Analysis

Table 3 summarises the association between potential risk factors and anti-EBOV IgG seropositivity using univariate analysis. Amongst the populations studied there was no statistically significant relationship between gender (p = 0.79), age (p = 0.96), travel (p = 0.62), household size (p = 0.39), exposure to rodents (p = 0.63) and the presence of IgG to EBOV. However, being a hunter (p = 0.01) was a risk factor, whereas the other occupations showed no statistical significance in univariate analysis. The use of simple mosquito nets had a protective effect. Importantly, significant association with bat contact or eating birds (p values respectively of <0.001 and 0.01) was identified.

Table 3. Association between potential risk factors and anti-EBOV IgG seropositivity.

Stratified Analysis

Seropositivity in age-groups was as follows: 2.7% in 18–29yo, 2.1% in 30–39yo, 2.3% in 40–49yo, 3.2% in 50–59yo and 0.0% in >60yo, with no evidence for an increase of seroprevalence with age. In the 18–29yo age-group, higher seroprevalence was associated with touching bats (p<0.001). In the second group (30–39yo), higher seroprevalence was associated with the military profession (p = 0.04). No significant association was found in the other age-groups. No significant association was identified in a stratified analysis by occupation, including military profession.

Regarding stratification by areas: in Pointe-Noire, to be a student (p = 0.002) or to have exposure to bats (p<0.001) was statistically associated with anti-EBOV IgG. Exposure to bats (p<0.001) was also found to be a risk factor in Brazzaville. Other variables (sex, age, household size, type of house, travel risk, exposure to rodents, and consumption of forest animals) were not significantly associated with the presence of IgG, regardless of the area in which donors lived.

Concerning stratification by gender (S1 Table), seropositivity was 2.6% in males and 2.0% in females. No significant association was identified in females. Amongst the male subpopulation, being a hunter (p = 0.009), having contact with bats (p<0.001) or monkeys (p = 0.01), or consuming birds (p = 0.002) was statistically associated with EBOV IgG positivity. Other variables (age, household size, type of house, travel risk, exposure to rodents) had no statistically significant relationship with the presence of IgG to EBOV.

Multivariate Analysis

In the multivariate model (Table 3), the only variables independently associated with Ebola antibody detection were contact with bats (p<0.001) and bird consumption (p = 0.04).


Whilst the Democratic Republic of the Congo and neighbouring Angola have experienced Marburg disease outbreaks [2,45], no Marburg cases have been reported to date in the Republic of Congo. By contrast, human epidemics due to Ebola virus have been reported in the Republic of Congo in 2001, 2002 and 2003. All outbreaks were located in the Cuvette-Ouest Department [1,29,46].

Against this background, we conducted a seroprevalence study of Ebola and Marburg viruses amongst blood donors in the Republic of Congo, to estimate the seroprevalence of both viruses outside the epidemic period and also to identify possible risk factors. This study has some obvious limitations related to the population studied (e.g., the number of blood donors originating from rural areas was small, all participants were older than 18 years old and 75% were males) and to the capacity to collect epidemiological information without interfering with the process of blood donation (for example, travel inside the country and activities outside the main occupation were not documented). However a body of standardised information was obtained from the questionnaires.

Importantly, our biological analyses identified antibodies specific for Ebola virus (and to a lesser extent to Marburg virus) in healthy blood donors who did not report a history of haemorrhagic fever. This confirms previous studies suggesting that filoviruses can circulate in Africa in the absence of severe clinical presentations (i.e., associated with asymptomatic or mild infections) [47] and that Ebola virus-specific seroconversion can be observed without clinical manifestation [21] or possibly associated with atypical clinical presentation. In the case of Ebola virus infections, asymptomatic seropositives have been identified by different techniques (e.g., immunofluorescence [22] or ELISA [21]) and have been found more frequently in areas where Ebola cases were reported [40]. In addition, Leroy and collaborators detected the Ebola virus genome in white blood cells of asymptomatic seroconverters investigated for up to 3 weeks following exposure to documented Ebola symptomatic patients [41]. Contact with limited amounts of virus, specific infection routes [48], specific characteristics of individual immunity leading to production of specific IgG and early and strong inflammatory responses [47], may explain the presence or absence of symptomatic presentation. Finally, a recent study identified asymptomatic seropositives with antibodies against various linear epitopes located in different and both structural and non-structural EBOV proteins [49]. Altogether, this rules out the hypothesis that antibodies to EBOV detected in asymptomatic individuals in previous studies are massively false positives.

It has been proposed that some populations may have been exposed to yet unidentified virus strains that have relatively low pathogenicity for humans. Monath [50] proposed that pathogenic strains may have independent transmission cycles involving species rarely in contact with humans. In support of this hypothesis, Gonzalez [22] reported atypical serological responses in asymptomatic seropositives, consisting in identical titres against Ebola Mayinga from Zaire and Ebola Boniface from Sudan identified in 89% of cases. This hypothesis still stands but is weakened by (i) the fact that fifteen years of investigations of African wildlife species have failed to identify such low pathogenicity strains in host species in close contact with humans and (ii) the identification of asymptomatic seroconversions following contact with symptomatic patients [41].

Monath [50] further proposed that pathogenic strains may emerge from non-pathogenic strains by mutational events, but this hypothesis is weakened by the argument that the same strain of EBOV has been shown to be responsible for symptomatic cases and secondary asymptomatic cases [41].

In the late 1980's, Gonzalez and collaborators identified low MARV seroprevalence values in Pointe Noire and Brazzaville (3 and 0%, respectively) [22]. In our study, the prevalence of IgG to MARV was also low (0.5%) and could not be associated with specific risk factors. In contrast, the prevalence of antibodies to EBOV was 2.5%, peaking at 4% in rural populations and in the city of Pointe Noire. It was 1.6% in Brazzaville. Gonzalez and collaborators had previously reported 7.8 and 6.2% Ebola seroprevalence values in Pointe Noire and Brazzaville, respectively [22]. The differences observed may be explained by different technical protocols used for detection of antibodies, by the fact that studies were performed more than twenty years apart, and by the investigation of different populations since Gonzalez studied randomly selected clusters (providing representativeness of gender and age distribution). Against the latter hypothesis, it should be noted that, in both studies, no significant difference associated with age-group and gender could be identified.

Nevertheless, two remarkable aspects of our epidemiological observations deserve further discussion. On the one hand, antibodies to Ebola virus were detected in urban populations of Congolese blood donors, which should stimulate future investigations relating to asymptomatic seropositives. On the other hand, new environmental factors associated with seropositivity have been identified. In neighbouring Gabon, the seroprevalence was significantly higher in the forest regions (17.6%) than in savannah regions (10.5%) and Lakeland areas (2.7%) [40,48], but no sociodemographic or behavioural risk factors associated with EBOV seropositivity could be identified. Therefore, the finding in the current study that (i) exposure to bats and (ii) bird consumption are associated independently in multivariate analysis with an increased prevalence of antibodies to EBOV is of particular relevance.

The notion of bird consumption must be interpreted with caution. If birds are consumed, they will have been cooked, but bird consumption also implies contact with birds, either in the markets in Africa or when capturing them or preparing them for cooking. Whilst further studies to clarify the role of birds as a possible source of human infection are clearly justified, we prefer to refer to “exposure to birds” as a potential source of the detected seropositivity.

The possibility of exposure to birds, with supporting evidence, has never been described before as a risk factor for filovirus infection. To the best of our knowledge, birds have not been associated with EBOV or virus antigen in previous investigations [51]. In 1979 and 1980, a total of 1,664 animals (117 species, including 67 birds) were collected in the DRC and Cameroon during the dry season near the site of the 1976 Ebola haemorrhagic fever epidemic. This study failed to identify an animal reservoir of EBOV [52]. An ecologic investigation was also performed to identify the reservoir of EBOV following the 1995 outbreak in Kikwit, DRC. Most of the 3,066 collected specimens were mammals (87%, 2663), but birds (9%, 265) were also collected. All attempts at isolation of EBOV remained negative [53]. During a study in CAR (Ngotto forest) in 1998–99, 662 animals were trapped including 16 birds. Only Zaire ebolavirus nucleotide sequences were detected in six organs rodents [54]. Finally, experimental inoculation of birds with EBOV did not evidence significant acute or chronic replication [55].

In 1994, an outbreak of Ebola was described in a wild chimpanzee community in the Taï National Park, Ivory Coast. Before the beginning of the outbreak, chimpanzees spent a long time in a fig tree (Ficus goliath) that was full of fruits. Many birds (pigeons) were seen feeding on the figs during the day, and rodents and fruit bats were feeding on the tree during the night. It was proposed that the F. goliath could have constituted an epidemiological "hub", putting different species-including birds- in contact with one another [56].

The implication of birds in the epidemiology of filoviral disease was evoked by Monath [50] in a hypothetical transmission cycle, taking into consideration the possibility that filoviruses may be primary arthropod or plant viruses, transmitted to vertebrates including bats or other insectivorous species such as birds. Jeffers et al. [57] reported in 2002 a noticeable biochemical similarity between the glycoprotein of certain birds, oncogenic retroviruses and the EBOV glycoprotein. They suggested a possible common evolutionary origin which could be an indication that avian species have or have had a role in the ecology and evolution of filoviruses. Accordingly, the possible role of birds in the transmission of EBOV should not be ruled out and our intriguing observation suggests that additional studies to elucidate the ecology of filoviruses in birds would be of great interest.

The statistically significant identification of exposure to bats as an independent risk factor for EBOV infection is also remarkable since contact with bats has been reported as a risk factor for MARV infection [58,59,60,61], and fruit bats [6] (and possibly insectivorous bats [62]) are thought to have a significant role in the ecological cycle of EBOV. Therefore, the current study reinforces the suspected importance of bats in the natural cycle of Ebola virus and its possible transmission to humans.

In Conclusion

Our results imply that in the Republic of Congo, the circulation of Marburg virus occurs at a very low rate without any identified risk factor, but that human exposure to Ebola virus without consequent disease is not infrequent. Living in Pointe Noire or in a rural area, and having contact with bats and birds is associated with a higher risk of exposure to Ebola virus. Unfortunately, little is known about the natural history and biological properties of EBOV antibody in individuals without haemorrhagic fever. Here, we did not observe an increase of seroprevalence with age, which may suggest that, in some individuals, the antibody titre decreases and becomes undetectable with time. This would in turn imply the absence of iterative contacts with Ebola virus antigens or that of a strong antibody response following such secondary antigenic exposure.

Similarly, the protection afforded by antibodies detected in blood donors against Ebola virus infection remains completely unknown. How individuals without any history of haemorrhagic fever acquire specific antibodies to EBOV and what are the biological properties of such antibodies (in particular what is their seroneutralising capacity) deserve further investigations in African populations.

Supporting Information

S1 Table. Associated anti-EBOV IgG seropositivity and potential risk factors stratified by gender (male).


S1 Checklist. Checklist of items included in report.



The authors are deeply indebted to the personnel of the Centre National de Transfusion Sanguine for their collaboration and assistance, to Dr. Stephan Becker (Institute of Virology, University of Marburg) for providing the anti-NP-Ebola mouse monoclonal antibody, to Corinna Thome-Bolduan (Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany) for technical assistance during serological analyses and to Anderson Loundou (Faculty of Medicine, Marseille, France) for technical assistance in database management. We acknowledge a contribution from the EU 7th Framework Predemics Project—Agreement No. 278433.

Author Contributions

Conceived and designed the experiments: NM ADL XdL. Performed the experiments: NM PE YD. Analyzed the data: NM HR LT YB. Contributed reagents/materials/analysis tools: XdL ADL PE SG PG. Wrote the paper: NM LT PE YB EAG XdL.


  1. 1. Chronology of Ebola Hemorrhagic Fever Outbreaks.
  2. 2. Chronology of Marburg Hemorrhagic Fever Outbreaks.
  3. 3. Siegert R (1978) [Marburg, Lassa and Ebola virus as cause of hemorrhagic fever]. Dtsch Med Wochenschr 103: 1176–1181. pmid:352653
  4. 4. Peterson AT, Carroll DS, Mills JN, Johnson KM (2004) Potential mammalian filovirus reservoirs. Emerg Infect Dis 10: 2073–2081. pmid:15663841
  5. 5. Smith I, Wang LF (2013) Bats and their virome: an important source of emerging viruses capable of infecting humans. Curr Opin Virol 3: 84–91. pmid:23265969
  6. 6. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, et al. (2005) Fruit bats as reservoirs of Ebola virus. Nature 438: 575–576. pmid:16319873
  7. 7. Pourrut X, Souris M, Towner JS, Rollin PE, Nichol ST, et al. (2009) Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis 9: 159. pmid:19785757
  8. 8. Olival KJ, Islam A, Yu M, Anthony SJ, Epstein JH, et al. (2013) Ebola virus antibodies in fruit bats, bangladesh. Emerg Infect Dis 19: 270–273. pmid:23343532
  9. 9. Yuan J, Zhang Y, Li J, Wang LF, Shi Z (2012) Serological evidence of ebolavirus infection in bats, China. Virol J 9: 236. pmid:23062147
  10. 10. Leroy EM, Rouquet P, Formenty P, Souquiere S, Kilbourne A, et al. (2004) Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 303: 387–390. pmid:14726594
  11. 11. Bukreyev AA, Chandran K, Dolnik O, Dye JM, Ebihara H, et al. (2014) Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012-June 2013. Arch Virol 159: 821–830. pmid:24122154
  12. 12. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, et al. (2010) Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155: 2083–2103. pmid:21046175
  13. 13. Martini GA (1969) Marburg agent disease: in man. Trans R Soc Trop Med Hyg 63: 295–302. pmid:5815873
  14. 14. Siegert R, Shu HL, Slenczka HL, Peters D, Muller G (1968) The aetiology of an unknown human infection transmitted by monkeys (preliminary communication). Ger Med Mon 13: 1–2. pmid:4968593
  15. 15. (1999) Viral haemorrhagic fever/Marburg, Democratic Republic of the Congo. Wkly Epidemiol Rec 74: 157–158. pmid:10355355
  16. 16. Bausch DG, Nichol ST, Muyembe-Tamfum JJ, Borchert M, Rollin PE, et al. (2006) Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 355: 909–919. pmid:16943403
  17. 17. (2005) Marburg haemorrhagic fever, Angola. Wkly Epidemiol Rec 80: 158–159. pmid:15898301
  18. 18. Towner JS, Khristova ML, Sealy TK, Vincent MJ, Erickson BR, et al. (2006) Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol 80: 6497–6516. pmid:16775337
  19. 19. Tomori O, Fabiyi A, Sorungbe A, Smith A, McCormick JB (1988) Viral hemorrhagic fever antibodies in Nigerian populations. Am J Trop Med Hyg 38: 407–410. pmid:3128130
  20. 20. Bausch DG, Borchert M, Grein T, Roth C, Swanepoel R, et al. (2003) Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg Infect Dis 9: 1531–1537. pmid:14720391
  21. 21. Gonzalez JP, Nakoune E, Slenczka W, Vidal P, Morvan JM (2000) Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic. Microbes Infect 2: 39–44. pmid:10717539
  22. 22. Gonzalez JP, Josse R, Johnson ED, Merlin M, Georges AJ, et al. (1989) Antibody prevalence against haemorrhagic fever viruses in randomized representative Central African populations. Res Virol 140: 319–331. pmid:2505350
  23. 23. Miranda ME, White ME, Dayrit MM, Hayes CG, Ksiazek TG, et al. (1991) Seroepidemiological study of filovirus related to Ebola in the Philippines. Lancet 337: 425–426. pmid:1671441
  24. 24. (1978) Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 56: 247–270. pmid:307455
  25. 25. (1978) Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56: 271–293. pmid:307456
  26. 26. Heymann DL, Weisfeld JS, Webb PA, Johnson KM, Cairns T, et al. (1980) Ebola hemorrhagic fever: Tandala, Zaire, 1977–1978. J Infect Dis 142: 372–376. pmid:7441008
  27. 27. Georges AJ, Leroy EM, Renaut AA, Benissan CT, Nabias RJ, et al. (1999) Ebola hemorrhagic fever outbreaks in Gabon, 1994–1997: epidemiologic and health control issues. J Infect Dis 179 Suppl 1: S65–75. pmid:9988167
  28. 28. Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, et al. (1999) The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179 Suppl 1: S76–86. pmid:9988168
  29. 29. Formenty P, Libama F, Epelboin A, Allarangar Y, Leroy E, et al. (2003) [Outbreak of Ebola hemorrhagic fever in the Republic of the Congo, 2003: a new strategy?]. Med Trop (Mars) 63: 291–295. pmid:14579469
  30. 30. Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, et al. (1995) Isolation and partial characterisation of a new strain of Ebola virus. Lancet 345: 1271–1274. pmid:7746057
  31. 31. Shoemaker T, MacNeil A, Balinandi S, Campbell S, Wamala JF, et al. (2012) Reemerging Sudan Ebola virus disease in Uganda, 2011. Emerg Infect Dis 18: 1480–1483. pmid:22931687
  32. 32. (2005) Outbreak of Ebola haemorrhagic fever in Yambio, south Sudan, April—June 2004. Wkly Epidemiol Rec 80: 370–375. pmid:16285261
  33. 33. Bosch X (2004) Sudan Ebola outbreak of known strain. Lancet Infect Dis 4: 388. pmid:15252932
  34. 34. Bagcchi S (2014) Ebola haemorrhagic fever in west Africa. Lancet Infect Dis 14: 375. pmid:24877203
  35. 35. Pourrut X, Kumulungui B, Wittmann T, Moussavou G, Delicat A, et al. (2005) The natural history of Ebola virus in Africa. Microbes Infect 7: 1005–1014. pmid:16002313
  36. 36. Nkoghe D, Kone ML, Yada A, Leroy E (2011) A limited outbreak of Ebola haemorrhagic fever in Etoumbi, Republic of Congo, 2005. Trans R Soc Trop Med Hyg 105: 466–472. pmid:21605882
  37. 37. Ebola Hemorrhagic Fever Distribution Map.
  38. 38. Bouree P, Bergmann JF (1983) Ebola virus infection in man: a serological and epidemiological survey in the Cameroons. Am J Trop Med Hyg 32: 1465–1466. pmid:6650749
  39. 39. Busico KM, Marshall KL, Ksiazek TG, Roels TH, Fleerackers Y, et al. (1999) Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. J Infect Dis 179 Suppl 1: S102–107. pmid:9988172
  40. 40. Becquart P, Wauquier N, Mahlakoiv T, Nkoghe D, Padilla C, et al. (2010) High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One 5: e9126. pmid:20161740
  41. 41. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E (2001) Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 124: 453–460. pmid:11472407
  42. 42. Schoepp RJ, Rossi CA, Khan SH, Goba A, Fair JN (2014) Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerg Infect Dis 20: 1176–1182. pmid:24959946
  43. 43. Emmerich P, Gunther S, Schmitz H (2008) Strain-specific antibody response to Lassa virus in the local population of west Africa. J Clin Virol 42: 40–44. pmid:18164653
  44. 44. Emmerich P, Thome-Bolduan C, Drosten C, Gunther S, Ban E, et al. (2006) Reverse ELISA for IgG and IgM antibodies to detect Lassa virus infections in Africa. J Clin Virol 37: 277–281. pmid:16996789
  45. 45. Marburg Hemorrhagic Fever Distribution Map.
  46. 46. (2003) Outbreak(s) of Ebola haemorrhagic fever, Congo and Gabon, October 2001-July 2002. Wkly Epidemiol Rec 78: 223–228. pmid:15571171
  47. 47. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, et al. (2000) Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355: 2210–2215. pmid:10881895
  48. 48. Nkoghe D, Padilla C, Becquart P, Wauquier N, Moussavou G, et al. (2011) Risk factors for Zaire ebolavirus--specific IgG in rural Gabonese populations. J Infect Dis 204 Suppl 3: S768–775. pmid:21987749
  49. 49. Becquart P, Mahlakoiv T, Nkoghe D, Leroy EM (2014) Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus. PLoS One 9: e96360. pmid:24914933
  50. 50. Monath TP (1999) Ecology of Marburg and Ebola viruses: speculations and directions for future research. J Infect Dis 179 Suppl 1: S127–138. pmid:9988176
  51. 51. Morvan JM, Deubel V, Gounon P, Nakoune E, Barriere P, et al. (1999) Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic. Microbes Infect 1: 1193–1201. pmid:10580275
  52. 52. Breman JG, Johnson KM, van der Groen G, Robbins CB, Szczeniowski MV, et al. (1999) A search for Ebola virus in animals in the Democratic Republic of the Congo and Cameroon: ecologic, virologic, and serologic surveys, 1979–1980. Ebola Virus Study Teams. J Infect Dis 179 Suppl 1: S139–147. pmid:9988177
  53. 53. Leirs H, Mills JN, Krebs JW, Childs JE, Akaibe D, et al. (1999) Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. J Infect Dis 179 Suppl 1: S155–163. pmid:9988179
  54. 54. Morvan JM NE, Deubel V & Colyn M (2000) Ecosystemes forestiers et virus Ebola. Bulletin de la Societé de Pathologie Exotique 93: 172–175.
  55. 55. Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, et al. (1996) Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 2: 321–325. pmid:8969248
  56. 56. Formenty P BC, Wyers M, Steiner C, Donati F, Dind F, Walker F, Le Guenno B (1999) Ebola virus outbreak among wild chimpanzees living in a rain forest of Côte d'Ivoire. J Infect Dis 179: 120–126.
  57. 57. Jeffers SA, Sanders DA, Sanchez A (2002) Covalent modifications of the ebola virus glycoprotein. J Virol 76: 12463–12472. pmid:12438572
  58. 58. Timen A, Koopmans MP, Vossen AC, van Doornum GJ, Gunther S, et al. (2009) Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis 15: 1171–1175. pmid:19751577
  59. 59. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, et al. (2009) Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 9: 723–728. pmid:19323614
  60. 60. Adjemian J, Farnon EC, Tschioko F, Wamala JF, Byaruhanga E, et al. (2011) Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007. J Infect Dis 204 Suppl 3: S796–799. pmid:21987753
  61. 61. Towner JS, Pourrut X, Albarino CG, Nkogue CN, Bird BH, et al. (2007) Marburg virus infection detected in a common African bat. PLoS One 2: e764. pmid:17712412
  62. 62. Saez AM, Weiss S, Nowak K, Lapeyre V, Zimmermann F, et al. (2014) Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med.